ArticleAntimicrobial agents and chemotherapy2022
Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits.
Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Treatment Patterns and Clinical Outcomes in Children withMicroorganisms · 2026Article
- Update on the comparativeJAC-antimicrobial resistance · 2026Article
- Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Efficacy of cefiderocol and levofloxacin againstAntimicrobial agents and chemotherapy · 2026Article
- Review
- Article
- A Retrospective Study of Cefiderocol Utilization and Associated Outcomes at an Academic Medical Center.Infectious disease reports · 2025Article
- Case Commentary: Overcoming intrinsic resistance-the successful use of aztreonam and avibactam forAntimicrobial agents and chemotherapy · 2025Article
- Epidemiology and Antimicrobial Resistance of Stenotrophomonas maltophilia in China, 2014-2021.Infectious diseases and therapy · 2025Article
- Development of rabbit models of ventilator-associated bacterial pneumonia produced by carbapenem-resistantAntimicrobial agents and chemotherapy · 2024Article
- Successful Treatment of PersistentOpen forum infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stenotrophomonas maltophilia is an important cause of pneumonia in immunocompromised patients. Cefiderocol is a parenteral siderophore cephalosporin with potent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.